AMA Expands Advanced Wound Care Portfolio with ActiGraft (ActiGraft+ and ActiGraftPRO)
At Advanced Medical Administration, we are committed to equipping wound care providers with clinically appropriate, compliant, and evidence-based solutions.
We’re pleased to announce that ActiGraft (ActiGraft+ and ActiGraftPRO) has officially been added to our advanced wound care portfolio.
This addition expands our ability to support providers managing complex, non-healing wounds, particularly diabetic foot ulcers, with an autologous option backed by randomized controlled trial data.
A Personalized, Autologous Approach
ActiGraft is an autologous whole blood clot therapy prepared at the point of care from a patient’s own peripheral blood.
Once applied to the wound bed, the clot serves as a protective covering designed to support the body’s natural wound healing processes. Because it is created from the patient’s own blood:
It is fully autologous
It contains the patient’s own cellular components
It avoids donor tissue
It may be appropriate for patients with religious or biologic sensitivities
ActiGraft+ and ActiGraftPRO offer the same core autologous technology, designed for flexibility across clinical settings.
Supported by Randomized Controlled Trial Data
ActiGraft has been evaluated in a multicenter randomized controlled trial involving hard-to-heal diabetic foot ulcers.
Key findings included:
Higher complete wound closure rates compared to standard of care
Statistically significant improvement in healing outcomes
Favorable safety profile
Improved durability of wound closure
(Full clinical data available upon request.)
While no wound therapy guarantees outcomes, we prioritize technologies supported by credible clinical evaluation, and ActiGraft meets that standard.
Designed for Today’s Wound Clinics
ActiGraft offers several practical advantages:
Point-of-care preparation
No centrifuge required
Approximately 5-minute coagulation time
Flexible application up to 56 cm²
Compatible with standard wound care workflows
For hospital outpatient departments, ActiGraftPRO aligns with NCD 270.3 as a blood-derived product for non-healing diabetic wounds, when used in accordance with coverage criteria and medical necessity.
As always, providers should consult current Medicare and commercial payer guidance and ensure proper documentation when selecting treatment options.
How ActiGraft Works
ActiGraft is created at the point of care by mixing fresh whole blood with proprietary coagulation components to form a whole blood clot, which is then applied directly to the wound surface.
The clot:
Provides a biologic scaffold
Supports the natural healing cascade
Serves as a protective covering
Instructional Video: How to Prepare and Apply ActiGraft
Expanding Options. Supporting Providers.
At AMA, our role is not to replace clinical judgment, it’s to expand access to clinically appropriate options.
By adding ActiGraft (ActiGraft+ and ActiGraftPRO) to our portfolio, we’re strengthening our ability to support:
Office-based wound clinics
Mobile wound care providers
Hospital outpatient departments
Providers managing complex, non-healing DFUs
If you’d like to learn whether ActiGraft is appropriate for your patient population or practice setting, our team is available to provide clinical information, workflow support, and coverage guidance.
Contact our team to learn more about integrating ActiGraft into your wound care program.
